Antiangiogenesis as the novel mechanism for justicidin A in the anticancer effect on human bladder cancer

Yi Wen Wang, Jing Jing Chuang, Tsuey Yu Chang, Shen Jeu Won, Hung Wen Tsai, Chung Ta Lee, Hong Lin Cheng, Tzong Shin Tzai, Hsiao-Sheng Liu, Nan Haw Chow

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Justicidin A (JA) is one of the methanol extracts of Justicia procumbens and was reported to induce apoptosis and inhibit the proliferation of human colon cancer cells. Using bladder cancer as a paradigm, this study was designed to identify the novel molecular basis underlying the antiangiogenic activities of JA and its potential in cancer therapy. Human bladder cancer cell lines (TSGH8301 and RT4) and immortalized uroepithelial cell lines (E6 and E7) were chosen to investigate the efficacy of JA in cell proliferation, apoptosis, and angiogenesis in vitro. The biological effects of JA treatment in vivo were examined using a xenograft tumor model in SCID mice. JA showed a dose-dependent and time-dependent inhibition of cell proliferation on TSGH8301 cancer cells, with IC50 values determined to be 0.44 μmol/l. Of interest,TSGH8301 cancer cells were more sensitive to JA than E7 immortalized uroepithelial cells, especially at lower concentrations. We further showed that JA inhibited the autocrine production of angiogenic factors and matrix-degrading enzymes in vitro and microvessel density in SCID mice in vivo (P< 0.01). Both differential cytotoxicity and angiogenesis inhibition of JA were confirmed by SCID mice experiments. Together, JA showed antiangiogenesis in vitro and in vivo through pleiotropic positive and negative regulators of angiogenesis molecules. The current investigation supports the potential of JA as an alternative chemoprevention agent for human bladder cancer.

Original languageEnglish
Pages (from-to)428-436
Number of pages9
JournalAnti-Cancer Drugs
Volume26
Issue number4
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Urinary Bladder Neoplasms
SCID Mice
Justicia
Neoplasms
Cell Proliferation
justicidin A
Apoptosis
Cell Line
Angiogenesis Inducing Agents
Chemoprevention
Microvessels
Heterografts
Colonic Neoplasms
Inhibitory Concentration 50
Methanol
Enzymes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Wang, Yi Wen ; Chuang, Jing Jing ; Chang, Tsuey Yu ; Won, Shen Jeu ; Tsai, Hung Wen ; Lee, Chung Ta ; Cheng, Hong Lin ; Tzai, Tzong Shin ; Liu, Hsiao-Sheng ; Chow, Nan Haw. / Antiangiogenesis as the novel mechanism for justicidin A in the anticancer effect on human bladder cancer. In: Anti-Cancer Drugs. 2015 ; Vol. 26, No. 4. pp. 428-436.
@article{d61f3628bc614550958c946f20ff5ddb,
title = "Antiangiogenesis as the novel mechanism for justicidin A in the anticancer effect on human bladder cancer",
abstract = "Justicidin A (JA) is one of the methanol extracts of Justicia procumbens and was reported to induce apoptosis and inhibit the proliferation of human colon cancer cells. Using bladder cancer as a paradigm, this study was designed to identify the novel molecular basis underlying the antiangiogenic activities of JA and its potential in cancer therapy. Human bladder cancer cell lines (TSGH8301 and RT4) and immortalized uroepithelial cell lines (E6 and E7) were chosen to investigate the efficacy of JA in cell proliferation, apoptosis, and angiogenesis in vitro. The biological effects of JA treatment in vivo were examined using a xenograft tumor model in SCID mice. JA showed a dose-dependent and time-dependent inhibition of cell proliferation on TSGH8301 cancer cells, with IC50 values determined to be 0.44 μmol/l. Of interest,TSGH8301 cancer cells were more sensitive to JA than E7 immortalized uroepithelial cells, especially at lower concentrations. We further showed that JA inhibited the autocrine production of angiogenic factors and matrix-degrading enzymes in vitro and microvessel density in SCID mice in vivo (P< 0.01). Both differential cytotoxicity and angiogenesis inhibition of JA were confirmed by SCID mice experiments. Together, JA showed antiangiogenesis in vitro and in vivo through pleiotropic positive and negative regulators of angiogenesis molecules. The current investigation supports the potential of JA as an alternative chemoprevention agent for human bladder cancer.",
author = "Wang, {Yi Wen} and Chuang, {Jing Jing} and Chang, {Tsuey Yu} and Won, {Shen Jeu} and Tsai, {Hung Wen} and Lee, {Chung Ta} and Cheng, {Hong Lin} and Tzai, {Tzong Shin} and Hsiao-Sheng Liu and Chow, {Nan Haw}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/CAD.0000000000000203",
language = "English",
volume = "26",
pages = "428--436",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Antiangiogenesis as the novel mechanism for justicidin A in the anticancer effect on human bladder cancer. / Wang, Yi Wen; Chuang, Jing Jing; Chang, Tsuey Yu; Won, Shen Jeu; Tsai, Hung Wen; Lee, Chung Ta; Cheng, Hong Lin; Tzai, Tzong Shin; Liu, Hsiao-Sheng; Chow, Nan Haw.

In: Anti-Cancer Drugs, Vol. 26, No. 4, 01.01.2015, p. 428-436.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antiangiogenesis as the novel mechanism for justicidin A in the anticancer effect on human bladder cancer

AU - Wang, Yi Wen

AU - Chuang, Jing Jing

AU - Chang, Tsuey Yu

AU - Won, Shen Jeu

AU - Tsai, Hung Wen

AU - Lee, Chung Ta

AU - Cheng, Hong Lin

AU - Tzai, Tzong Shin

AU - Liu, Hsiao-Sheng

AU - Chow, Nan Haw

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Justicidin A (JA) is one of the methanol extracts of Justicia procumbens and was reported to induce apoptosis and inhibit the proliferation of human colon cancer cells. Using bladder cancer as a paradigm, this study was designed to identify the novel molecular basis underlying the antiangiogenic activities of JA and its potential in cancer therapy. Human bladder cancer cell lines (TSGH8301 and RT4) and immortalized uroepithelial cell lines (E6 and E7) were chosen to investigate the efficacy of JA in cell proliferation, apoptosis, and angiogenesis in vitro. The biological effects of JA treatment in vivo were examined using a xenograft tumor model in SCID mice. JA showed a dose-dependent and time-dependent inhibition of cell proliferation on TSGH8301 cancer cells, with IC50 values determined to be 0.44 μmol/l. Of interest,TSGH8301 cancer cells were more sensitive to JA than E7 immortalized uroepithelial cells, especially at lower concentrations. We further showed that JA inhibited the autocrine production of angiogenic factors and matrix-degrading enzymes in vitro and microvessel density in SCID mice in vivo (P< 0.01). Both differential cytotoxicity and angiogenesis inhibition of JA were confirmed by SCID mice experiments. Together, JA showed antiangiogenesis in vitro and in vivo through pleiotropic positive and negative regulators of angiogenesis molecules. The current investigation supports the potential of JA as an alternative chemoprevention agent for human bladder cancer.

AB - Justicidin A (JA) is one of the methanol extracts of Justicia procumbens and was reported to induce apoptosis and inhibit the proliferation of human colon cancer cells. Using bladder cancer as a paradigm, this study was designed to identify the novel molecular basis underlying the antiangiogenic activities of JA and its potential in cancer therapy. Human bladder cancer cell lines (TSGH8301 and RT4) and immortalized uroepithelial cell lines (E6 and E7) were chosen to investigate the efficacy of JA in cell proliferation, apoptosis, and angiogenesis in vitro. The biological effects of JA treatment in vivo were examined using a xenograft tumor model in SCID mice. JA showed a dose-dependent and time-dependent inhibition of cell proliferation on TSGH8301 cancer cells, with IC50 values determined to be 0.44 μmol/l. Of interest,TSGH8301 cancer cells were more sensitive to JA than E7 immortalized uroepithelial cells, especially at lower concentrations. We further showed that JA inhibited the autocrine production of angiogenic factors and matrix-degrading enzymes in vitro and microvessel density in SCID mice in vivo (P< 0.01). Both differential cytotoxicity and angiogenesis inhibition of JA were confirmed by SCID mice experiments. Together, JA showed antiangiogenesis in vitro and in vivo through pleiotropic positive and negative regulators of angiogenesis molecules. The current investigation supports the potential of JA as an alternative chemoprevention agent for human bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=84925500400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925500400&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000203

DO - 10.1097/CAD.0000000000000203

M3 - Article

C2 - 25569706

AN - SCOPUS:84925500400

VL - 26

SP - 428

EP - 436

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -